Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Megestrol Acetate Plus LNG-IUS in Endometrial Atypical Hyperplasia
NCT03241888Phase 3Completed
- Sponsor
- Fudan University
- Start
- Jul 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of megestrol and avatrombopag in endometrial atypical hyperplasia (AEH) (3 arms), sponsored by Fudan University. Primary endpoints: Pathological response rate at 12 months and Pathological response time at 12 months. Started Jul 2017; status: completed.
02
Drugs
megestrolavatrombopag
03
Conditions
endometrial atypical hyperplasia (AEH)
Beyond the preview
Go deeper on NCT03241888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241888.